DE602005025911D1 - Kontrastmittel für eine extrazelluläre matrix - Google Patents

Kontrastmittel für eine extrazelluläre matrix

Info

Publication number
DE602005025911D1
DE602005025911D1 DE602005025911T DE602005025911T DE602005025911D1 DE 602005025911 D1 DE602005025911 D1 DE 602005025911D1 DE 602005025911 T DE602005025911 T DE 602005025911T DE 602005025911 T DE602005025911 T DE 602005025911T DE 602005025911 D1 DE602005025911 D1 DE 602005025911D1
Authority
DE
Germany
Prior art keywords
contrastant
extra
cellular matrix
biomodifier
areas
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602005025911T
Other languages
English (en)
Inventor
Dagfinn Loevhaug
Morten Eriksen
Hege Fjerdingstad
Andrew Healey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GE Healthcare AS
Original Assignee
GE Healthcare AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GE Healthcare AS filed Critical GE Healthcare AS
Publication of DE602005025911D1 publication Critical patent/DE602005025911D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Steroid Compounds (AREA)
DE602005025911T 2004-11-22 2005-11-21 Kontrastmittel für eine extrazelluläre matrix Active DE602005025911D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NO20045081 2004-11-22
PCT/NO2005/000435 WO2006054904A2 (en) 2004-11-22 2005-11-21 Contrast agents to target extracellular matrix

Publications (1)

Publication Number Publication Date
DE602005025911D1 true DE602005025911D1 (de) 2011-02-24

Family

ID=36182407

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005025911T Active DE602005025911D1 (de) 2004-11-22 2005-11-21 Kontrastmittel für eine extrazelluläre matrix

Country Status (17)

Country Link
US (1) US8182790B2 (de)
EP (2) EP1814598B1 (de)
JP (2) JP5116480B2 (de)
KR (1) KR20070091609A (de)
CN (1) CN101107016B (de)
AT (1) ATE494913T1 (de)
AU (1) AU2005307195A1 (de)
BR (1) BRPI0518328A2 (de)
CA (1) CA2586621A1 (de)
DE (1) DE602005025911D1 (de)
ES (1) ES2358745T3 (de)
IL (1) IL182898A0 (de)
MX (1) MX2007006050A (de)
NO (1) NO20073039L (de)
RU (1) RU2007118385A (de)
WO (1) WO2006054904A2 (de)
ZA (1) ZA200705043B (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0610395D0 (en) * 2006-05-25 2006-07-05 Ge Healthcare Ltd Novel imaging agents
EP2056886A2 (de) * 2006-08-28 2009-05-13 GE Healthcare Limited 68ga-markierte radiopharmazeutika auf peptidbasis
JP2008266194A (ja) * 2007-04-19 2008-11-06 Hiroshi Tanaka 分子プローブの原料として有用な新規有機化合物
GB0722650D0 (en) * 2007-11-19 2007-12-27 Ge Healthcare Ltd Novel imaging method
US8466258B2 (en) 2007-12-13 2013-06-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Polypeptides, cyclic polypeptides and pharmaceutical comprising thereof for non invasive specific imaging of fibrosis
DK2244741T3 (en) * 2008-01-18 2015-05-26 Visen Medical Inc Fluorescent imaging agents
JP5265762B2 (ja) 2008-05-13 2013-08-14 ユニバーシティ・オブ・カンザス 金属抽出ペプチド（ｍａｐ）タグおよび関連する方法
GB0814722D0 (en) * 2008-08-12 2008-09-17 Ge Healthcare Ltd Treatment monitoring
GB0910013D0 (en) * 2009-06-10 2009-07-22 Ge Healthcare Ltd PET imaging of fibogenesis
KR100991716B1 (ko) * 2009-10-22 2010-11-04 경북대학교 산학협력단 광학영상 조영제, 그 용도 및 장치
CN102504603B (zh) * 2011-10-20 2014-01-29 中国海洋大学 一种多聚物与生物染色剂的偶合物及其制备方法和用途
WO2013181461A2 (en) 2012-06-01 2013-12-05 University Of Kansas Metal abstraction peptide with superoxide dismutase activity
US20170050989A1 (en) * 2013-12-03 2017-02-23 The General Hospital Corporation Molecular Imaging Probes

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4647447A (en) 1981-07-24 1987-03-03 Schering Aktiengesellschaft Diagnostic media
US4615876A (en) * 1983-04-25 1986-10-07 Curators Of The University Of Missouri Macrocyclic complexes of technetium-99m for use as diagnostic radionuclides
US4687659A (en) 1984-11-13 1987-08-18 Salutar, Inc. Diamide-DTPA-paramagnetic contrast agents for MR imaging
US6048982A (en) 1986-04-18 2000-04-11 Carnegie Mellon University Cyanine dyes as labeling reagents for detection of biological and other materials by luminescence methods
US5268486A (en) 1986-04-18 1993-12-07 Carnegie-Mellon Unversity Method for labeling and detecting materials employing arylsulfonate cyanine dyes
AU641361B2 (en) 1988-05-02 1993-09-23 Zynaxis Technologies, Incorporated Compounds, compositions and method for binding bio-affecting substances to surface membranes of bio-particles
GB8903022D0 (en) 1989-02-10 1989-03-30 Celltech Ltd Chemical compounds
JP3682974B2 (ja) 1991-11-27 2005-08-17 株式会社ファノスディベロップメント バイオ作用性物質をバイオ粒子表面膜へ結合するための化合物、組成、および方法
EP1007101B1 (de) 1996-10-28 2006-05-17 GE Healthcare AS Verbesseringen an oder in verbindung mit diagnostischen/therapeutischen mitteln
ES2257771T3 (es) 1996-10-28 2006-08-01 Amersham Health As Agentes de contraste.
JP2001509796A (ja) * 1997-01-29 2001-07-24 ニユコメド・イメージング・アクシエセルカペト 重合体
US6348599B1 (en) 1997-07-28 2002-02-19 Nycomed Amersham Plc Cyanine dyes
US5942637A (en) 1998-03-30 1999-08-24 North Dakota State University Research Foundation Compounds containing tetradecachlorocyclohexasilane dianion
DE69940465D1 (de) * 1998-05-08 2009-04-09 Univ California Verfahren zum nachweis und hemmung der angiogenese
US6852318B1 (en) 1998-05-08 2005-02-08 The Regents Of The University Of California Methods for detecting and inhibiting angiogenesis
JP2000095758A (ja) * 1998-09-18 2000-04-04 Schering Ag 近赤外蛍光造影剤および蛍光造影方法
US6230777B1 (en) 1999-02-04 2001-05-15 Midmac Systems, Inc. Filter forming and joining apparatus
JP5043271B2 (ja) * 2000-04-12 2012-10-10 ジーイー・ヘルスケア・アクスイェ・セルスカプ ペプチドベースの化合物
NO20004795D0 (no) 2000-09-26 2000-09-26 Nycomed Imaging As Peptidbaserte forbindelser
JP2005506952A (ja) * 2000-11-27 2005-03-10 ブリストル−マイヤーズ・スクイブ・メディカル・イメージング・インコーポレイテッド 心臓潅流およびビトロネクチンレセプター標的造影剤の同時造影
HU230901B1 (hu) * 2001-07-10 2019-01-28 Ge Healthcare Limited Peptidalapú vegyületek és ezeket tartalmazó gyógyszerkészítmények
GB0116815D0 (en) 2001-07-10 2001-08-29 Nycomed Amersham Plc Improved chelator conjugates
GB0206750D0 (en) 2002-03-22 2002-05-01 Amersham Plc Radiofluorination methods
CA2488423A1 (en) 2002-06-17 2003-12-24 Cartela Ab Methods and uses of the integrin alpha 10 chain, for preventing progression of atherosclerosis plaque formation
US7063158B2 (en) 2003-06-16 2006-06-20 Deepwater Technologies, Inc. Bottom tensioned offshore oil well production riser
NO20033115D0 (no) * 2003-07-08 2003-07-08 Amersham Health As Peptid-baserte forbindelser
GB0317815D0 (en) * 2003-07-30 2003-09-03 Amersham Health As Imaging agents
WO2005019247A2 (en) * 2003-08-15 2005-03-03 Board Of Regents, The University Of Texas System Cyclic peptide and imaging compound compositions and uses for targeted imaging and therapy
WO2005049095A2 (en) * 2003-11-24 2005-06-02 Amersham Health As Contrast agent imaging angiotensin ii receptors
JP2007526300A (ja) * 2004-03-04 2007-09-13 ジーイー・ヘルスケア・アクスイェ・セルスカプ 医薬化合物
US8361443B2 (en) * 2004-06-16 2013-01-29 Ge Healthcare As Peptide-based compounds
WO2005123768A1 (en) * 2004-06-16 2005-12-29 Ge Healthcare As Peptide-based compounds

Also Published As

Publication number Publication date
ZA200705043B (en) 2008-09-25
RU2007118385A (ru) 2008-12-27
JP5116480B2 (ja) 2013-01-09
CA2586621A1 (en) 2006-05-26
JP2012207027A (ja) 2012-10-25
EP2243496A2 (de) 2010-10-27
JP2008520658A (ja) 2008-06-19
MX2007006050A (es) 2007-11-14
EP1814598A2 (de) 2007-08-08
AU2005307195A1 (en) 2006-05-26
CN101107016B (zh) 2011-11-16
EP1814598B1 (de) 2011-01-12
WO2006054904A3 (en) 2007-04-05
CN101107016A (zh) 2008-01-16
EP2243496A3 (de) 2012-12-26
ATE494913T1 (de) 2011-01-15
KR20070091609A (ko) 2007-09-11
IL182898A0 (en) 2007-08-19
ES2358745T3 (es) 2011-05-13
NO20073039L (no) 2007-08-16
US8182790B2 (en) 2012-05-22
WO2006054904A2 (en) 2006-05-26
BRPI0518328A2 (pt) 2008-11-11
US20090208412A1 (en) 2009-08-20

Similar Documents

Publication Publication Date Title
DE602005025911D1 (de) Kontrastmittel für eine extrazelluläre matrix
DE60042522D1 (de) Cyanin- oder indocyaninefarbstoffe biokonjugate für biomedische anwendungen
ECSP066311A (es) Derivados de la piperazina y su uso como agentes terapéuticos
ATE530168T1 (de) Magnetische nanoteilchen-zusammensetzungen und ihre verwendungen
DK1409544T3 (da) Humane DR4-antistoffer og anvendelser deraf
CY1114679T1 (el) Συνθεσεις για διαγνωση και θεραπεια ασθενειων που συνδυαζονται με παρεκκλινουσα εκφραση φουτρινων (r-σπονδινων)
GB0421639D0 (en) Methods and compositions relating to alzheimer's disease
IL173032A0 (en) Pyridazine derivatives and their use as therapeutic agents
WO2003049684A3 (en) Pseudo-antibody constructs
CY1109151T1 (el) Αντισωματα dr4 και χρησεις αυτων
BRPI0418552A (pt) compostos de alvejamento de piperidinila que seletivamente ligam-se à integrinas
NO20010021D0 (no) Trifunksjonelt reagens for konjugering til et biomolekyl
DE50207866D1 (de) Verwendung löslicher cytokeratin-1-fragmente in diagnostik
ATE376428T1 (de) Metallkomplexverbindungen
ATE425770T1 (de) Kontrastmittel
EP1837655A4 (de) Blockierter enzymsondenkomplex
JP2008509921A5 (de)
ATE277352T1 (de) Einetenascin-c isoform als marker für neoplasmen
DE602004029016D1 (de) Stq-peptide
EP1250091A4 (de) Hydrophile zyaninfarbstoffe
DE602008004556D1 (de) Zusammensetzungen und verfahren zum nachweis von störungen in verbindung mit histamin
ATE306283T1 (de) Biotin-derivate und ihre konjugaten mit chelatierungsmitteln
WO2005049095A3 (en) Contrast agent imaging angiotensin ii receptors
ATE454631T1 (de) Phosphorylierte sp1 als marker bei der diagnose nichtalkoholischer steatohepatitis (nash) und ziel beim drogenscreening auf nash
WO2007130589A3 (en) Nl, n4-bis (buta-i, 3-dienyl) butane-i, 4-diamine pharmaceutical compositions and uses thereof